Zhang Bin, Liu Yan-Xue, Cao Wen-Feng, Cao Xu-Chen, Ning Lian-Sheng, Hao Xi-Shan
Department of Breast Neoplasms, Cancer Hospital of Tianjin Medical University, Tianjin 300060, China.
Zhonghua Bing Li Xue Za Zhi. 2008 Jul;37(7):471-6.
The study was designed to investigate the expression patterns of metalloproteinase (MMP)-13 protein in invasive breast carcinoma and to determine the clinicopathological and prognostic values of its various localization and relation to the tumor phenotypes.
Immunohistochemistry was performed on paraffin-embedded tissue array from 263 invasive breast carcinomas to investigate the protein expressions of MMP-13, estrogen receptor, progesterone receptor, HER2, MMP-2, MMP-9 and tissue inhibitor of matrix metalloproteinases (TIMP)-1, TIMP-2.
MMP-13 protein was detected in the cytoplasm of carcinoma cells and peritumoral fibroblasts. High level expression of MMP-13 protein in tumor cells was associated with more lymph node involvement and higher tumor grade (both P < 0.01), and positively correlated with HER2 (P = 0.015) and TIMP-1 protein (P < 0.01) expression in carcinoma cells. Moreover, high expression of MMP-13 was associated with shortened overall survival for the entire patient population and the patient group with positive lymph node. Tumor cell derived MMP-13 had different impact on patients with different HER2 status. Peritumoral fibroblasts derived MMP-13 protein, although correlated with tumor cell derived MMP-13 and associated with lymph node stage and HER2 expression, was found having less prognostic impact. Univariate survival analysis showed that the tumor size, grade, lymph node status, PR status, HER2 expression, tumors TIMP-1 and MMP-13 expression were prognostic factors. However, multivariate survival analysis showed that only tumor size, lymph node status, HER2 expression, tumors TIMP-1 and MMP-13 were independent prognostic factors.
MMP-13 protein expressed by tumor cells correlates with the invasion and metastasis of breast carcinoma, and therefore, may serve as a poor prognostic marker for the patient.
本研究旨在调查基质金属蛋白酶(MMP)-13蛋白在浸润性乳腺癌中的表达模式,并确定其不同定位及其与肿瘤表型的关系的临床病理和预后价值。
对263例浸润性乳腺癌石蜡包埋组织芯片进行免疫组织化学检测,以研究MMP-13、雌激素受体、孕激素受体、HER2、MMP-2、MMP-9和基质金属蛋白酶组织抑制剂(TIMP)-1、TIMP-2的蛋白表达。
在癌细胞和肿瘤周围成纤维细胞的细胞质中检测到MMP-13蛋白。肿瘤细胞中MMP-13蛋白的高水平表达与更多的淋巴结受累和更高的肿瘤分级相关(均P<0.01),并且与癌细胞中HER2(P = 0.015)和TIMP-1蛋白(P<0.01)表达呈正相关。此外,MMP-13的高表达与整个患者群体以及淋巴结阳性患者组的总生存期缩短相关。肿瘤细胞来源的MMP-13对不同HER2状态的患者有不同影响。肿瘤周围成纤维细胞来源的MMP-13蛋白虽然与肿瘤细胞来源的MMP-13相关且与淋巴结分期和HER2表达相关,但发现其预后影响较小。单因素生存分析显示,肿瘤大小、分级、淋巴结状态、PR状态、HER2表达、肿瘤TIMP-1和MMP-13表达是预后因素。然而,多因素生存分析显示,只有肿瘤大小、淋巴结状态、HER2表达、肿瘤TIMP-1和MMP-13是独立的预后因素。
肿瘤细胞表达的MMP-13蛋白与乳腺癌的侵袭和转移相关,因此,可能作为患者预后不良的标志物。